Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Semin Oncol Nurs. 2019 Apr;35(2):217-219. doi: 10.1016/j.soncn.2019.02.009. Epub 2019 Mar 12.
To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies.
PubMed, FDA.gov, ASCO.org.
The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies.
Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.
回顾美国食品和药物管理局最近批准的用于治疗妇科恶性肿瘤的疗法。
PubMed、FDA.gov、ASCO.org。
治疗妇科恶性肿瘤的领域正在迅速变化。对于新诊断的和铂敏感的复发性卵巢癌完成化疗后，维持治疗现在可用于晚期卵巢癌患者。抗血管生成治疗在妇科恶性肿瘤中有多种应用。免疫疗法可用于某些情况下的妇科恶性肿瘤患者。
生物制剂和免疫疗法具有不同的副作用特征，护士需要了解这些特征，以优化患者的护理和结局。
